Cardiac Imaging · Practice & Markets

SCCT 2026: Value-Based Cardiac CT, AI, and the Structural Heart Pipeline

Clinical takeaways and physician-investor context from the Society of Cardiovascular Computed Tomography's 21st Annual Scientific Meeting

The Society of Cardiovascular Computed Tomography convened its 21st annual meeting this week in Chula Vista, just outside San Diego.

More than 1,100 attendees from around the world took part across 39 sessions spanning 15 clinical tracks.

The program's throughline was unmistakable: cardiac CT is being positioned as the value-based imaging modality of choice, and its growth is now inseparable from the artificial intelligence tools riding alongside it.

For practicing cardiologists, the meeting offered practical guidance on preprocedural planning, sex-specific imaging, and where AI-guided plaque and flow analysis now fits in everyday coronary workup.

For physician-investors, it was also a showcase of the commercial companies racing to own the AI layer sitting on top of every coronary CT angiogram.

Why Cardiac CT Is Being Framed as a Value Play

Meeting leadership repeatedly returned to a cost argument: cardiac CT scanners are already deployed in most hospitals and many outpatient clinics, unlike newer and pricier imaging platforms.

The program chair, quoted by TCTMD, argued that not every expensive tool in the cardiovascular armamentarium delivers proportionate gains in survival or quality of life.

A new prevention track was added to the 2026 program specifically to address how cardiac CT might eventually inform risk stratification in asymptomatic patients, even though the society acknowledges the evidence there remains unsettled.

Access, equity, and the environmental footprint of imaging — radiation dose, energy use, and emissions — were also formally worked into the agenda for the first time.

AI Takes Center Stage

A dedicated Saturday session billed as "AI on FIRE" covered large language models, photon-counting CT, and a live debate over whether human readers of coronary CT angiography will remain necessary at all.

Commercial AI-plaque analysis platforms had a heavy presence on the exhibit floor, reflecting how quickly this segment has moved from research abstract to reimbursed clinical tool.

Heartflow's FFR-CT and Plaque Analysis platform has been the most commercially visible entrant, and the company completed its Nasdaq initial public offering in August 2025 under the ticker HTFL.

Two competing plaque-quantification platforms, Cleerly and Elucid, also sponsored educational sessions at the meeting but remain privately held, so no public ticker exists for either.

A third exhibitor, Arineta, presented an office-based cardiac CT concept aimed at expanding preventive imaging access outside the hospital, and it too remains a private company.

Structural Heart Planning Gets Its Own Spotlight

A joint session with the American Society of Echocardiography focused squarely on CT-based preprocedural planning for TAVI, transcatheter mitral valve replacement, and transcatheter tricuspid valve replacement.

A separate joint session with the Society for Cardiovascular Angiography and Interventions addressed how CCTA can be used to plan revascularization strategy before the patient ever reaches the cath lab.

Pre-conference workshops on aortic, tricuspid, pulmonic, and left atrial appendage occlusion planning underscored that structural teams increasingly expect a CT-trained partner at the table before any device is sized.

Sex- and Gender-Specific Imaging

A dedicated session examined how hormonal transitions, pregnancy, and breast cancer treatment can each independently alter cardiovascular risk and imaging findings.

This reflects a broader push within the society to move sex- and gender-specific cardiovascular imaging from a niche interest into standard teaching content.

Session Snapshot

Table 1. Selected SCCT 2026 clinical sessions relevant to practicing cardiologists

Session	Focus	Practice Relevance
AI on FIRE	Large language models, photon-counting CT, human-vs-AI reader debate	Anticipate AI-augmented CCTA interpretation entering routine workflow
Structural planning (with ASE)	TAVI, transcatheter mitral and tricuspid replacement	Reinforces CT's role as the default preprocedural roadmap
CCTA in revascularization (with SCAI)	Using CT to plan PCI/CABG strategy	Supports earlier CT-based heart-team discussion
Sex and gender in CVD	Hormonal transitions, pregnancy, breast cancer therapy effects	Prompts more individualized risk assessment in women
Prevention track (new for 2026)	Cardiac CT in asymptomatic patients	Evidence still evolving; not yet a guideline-directed screen

Figure 1. Illustrative decision pathway showing where AI-augmented flow and plaque analysis layer onto standard CCTA workflow. Schematic for teaching purposes, not a validated algorithm.

The Physician-Investor Angle

Cardiac CT sits at the intersection of three publicly traded imaging hardware franchises and one newly public AI-software pure play.

GE HealthCare and Siemens Healthineers remain the dominant CT hardware vendors that most cardiac CT programs are already built on.

Heartflow is the clearest public proxy for the AI-software layer that now rides on top of that hardware.

Table 2. Publicly traded and private companies relevant to the cardiac CT ecosystem

Company	Ticker	Role in Cardiac CT	Analyst Consensus	Approx. Price Target
Heartflow, Inc.	NASDAQ: HTFL	AI-based FFR-CT and coronary plaque analysis software	Strong Buy	~$37–39
GE HealthCare Technologies	NASDAQ: GEHC	CT scanner hardware, enterprise imaging AI	Buy	~$79–82
Siemens Healthineers AG	OTC: SMMNY (ADR)	CT scanner hardware, photon-counting CT	Buy	— (ADR target not consistently published)
Cleerly, Inc.	No ticker (private)	AI-based coronary plaque quantification	—	—
Elucid, Inc.	No ticker (private)	AI-based vessel-wall and plaque-physiology analysis	—	—
Arineta Ltd.	No ticker (private)	Office-based, compact cardiac CT systems	—	—

Figure 2. Public-market exposure to cardiac CT is currently concentrated in hardware incumbents and a single AI-software pure play; the plaque-analysis competitive set remains largely private.

Case Vignette

A 52-year-old woman with atypical chest discomfort and an intermediate pretest probability is referred for CCTA rather than direct catheterization.

The scan is reported alongside an AI-based FFR-CT analysis, which shows a hemodynamically nonsignificant 60% stenosis in the mid-LAD.

Because she is perimenopausal, the reading cardiologist also factors in the sex-specific considerations highlighted at this year's meeting when interpreting plaque composition and symptom burden.

She is managed with optimized guideline-directed medical therapy and short-interval clinical follow-up rather than an invasive procedure, illustrating how AI-augmented CT can keep a patient out of the cath lab entirely.

Bottom Line

Cardiac CT is being explicitly positioned as the value-based front door to coronary and structural heart disease, with AI-based flow and plaque analysis now woven into routine interpretation rather than treated as investigational add-ons.

Clinically, expect more referrals arriving with AI-FFR or plaque quantification already attached, and expect structural and revascularization heart-team discussions to lean more heavily on CT planning up front.

On the investment side, Heartflow is now the cleanest public vehicle for the AI-software layer, while GE HealthCare and Siemens Healthineers remain the hardware backbone; the plaque-analysis competitive field otherwise remains private and untraded.

Physician education disclaimer: This article is intended for educational purposes for practicing clinicians and does not constitute individualized medical advice; treatment decisions should be based on full clinical context and current guidelines.

Financial disclaimer: Nothing in this article constitutes investment advice; stock prices, analyst ratings, and price targets are approximate, sourced from third-party financial data providers, subject to change, and should not be relied upon for investment decisions without independent verification.

References

1. TCTMD: SCCT 2026 — What to Expect in Chula Vista
2. Society of Cardiovascular Computed Tomography — Annual Scientific Meeting
3. StockAnalysis.com — Heartflow, Inc. (HTFL)
4. StockAnalysis.com — GE HealthCare Technologies (GEHC)
5. StockAnalysis.com — Siemens Healthineers AG (SMMNY)